CSPC Innovation: licensing lifts nine-month results, but Q3 swings back to a loss
According to TradingView, CSPC Innovation's nine-month revenue rose 149.62%, while the company returned to a RMB 51.3m net loss in the third quarter.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to TradingView, revenue at Chinese drugmaker CSPC Innovation Pharmaceutical rose 149.62% over the first nine months. Licensing revenue was a major driver of the increase.
Attributable net income for the nine months reached RMB 1.21bn. In the third quarter, however, the company posted an attributable net loss of RMB 51.3m, as research and development and financial expenses increased.
why it matters
Licensing payments can produce sharp revenue jumps, but they are irregular, so investors usually look at whether operating costs are sustainable. The return to a quarterly loss shows that rising R&D spending is not yet offset by licensing income.
market impact
CSPC shares and Hong Kong pharma sector: strong licensing income supports reported results, but higher spending weighs on quarterly profit
tags
instruments
sources
- CSPC Innovation Pharmaceutical: Licensing revenue propelled 9M growth, while Q3 returned to an attributable net loss — TradingView, 28 October 2026 at 09:03 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗